Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Helix BioPharma Corp.TSX: HBP.TO
Total Assets · Q3 FY2026 · quarter ended Apr 2026
Total assets rises 2019.1% from a year ago
Total assets stood at CA$21.38M at the end of Q3 FY2026, up 2019.1% from a year earlier and up 15.4% from the prior quarter. Over 3 fiscal years it compounded at +71.5% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +2019.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
CAD · from the balance sheet
- Latest · FY2025
- 18.8M CAD
- Year-over-year change
- +1162.7%
- 4-year CAGR
- +46.7%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 18.8M | +1162.7% |
| FY2024 | 2024-07-31 | 1.49M | +44.7% |
| FY2023 | 2023-07-31 | 1.03M | -72.4% |
| FY2022 | 2022-07-31 | 3.73M | -8.2% |
| FY2021 | 2021-07-31 | 4.07M | — |
Total Assets vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
- Its year-over-year change of +2019.1% is the highest of 5, against a peer median of +4.3%.
- Over three fiscal years its annual growth of +71.5% compares with a peer median of -22.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $131.18M USD | -14.8% | -17.2% | |
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | $75.28M USD | +69.7% | +72.5% |
| Mar 2026 | CA$31.41M CAD | +23.4% | -27.5% | |
| Apr 2026 | CA$21.38M CAD | +2019.1% | +71.5% | |
| Apr 2026 | CA$1.53M CAD | -60.4% | -75.6% | |
| Peer median (excluding HBP.TO) | — | +4.3% | -22.3% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.